Zacks Research Weighs in on Novartis AG’s Q3 2026 Earnings (NYSE:NVS)

Novartis AG (NYSE:NVS) – Equities researchers at Zacks Research cut their Q3 2026 earnings estimates for shares of Novartis in a research note issued to investors on Monday, September 30th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings of $2.37 per share for the quarter, down from their previous estimate of $2.38. The consensus estimate for Novartis’ current full-year earnings is $7.50 per share. Zacks Research also issued estimates for Novartis’ FY2026 earnings at $8.94 EPS.

NVS has been the subject of several other research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Novartis in a research note on Friday, July 19th. Bank of America downgraded shares of Novartis from a “buy” rating to a “neutral” rating and cut their target price for the company from $135.00 to $130.00 in a research note on Wednesday, September 11th. The Goldman Sachs Group reissued a “neutral” rating and issued a $121.00 target price (up previously from $119.00) on shares of Novartis in a research note on Thursday, September 5th. Barclays raised shares of Novartis to a “strong sell” rating in a research note on Monday, June 24th. Finally, Jefferies Financial Group downgraded shares of Novartis from a “buy” rating to a “hold” rating in a research note on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has issued a strong buy rating to the stock. According to MarketBeat, Novartis has a consensus rating of “Hold” and a consensus price target of $120.70.

Novartis Trading Up 0.1 %

NYSE:NVS opened at $113.93 on Thursday. The company has a market capitalization of $232.87 billion, a PE ratio of 15.38, a price-to-earnings-growth ratio of 1.73 and a beta of 0.57. The company has a quick ratio of 0.72, a current ratio of 0.93 and a debt-to-equity ratio of 0.47. Novartis has a 52-week low of $92.19 and a 52-week high of $120.92. The stock has a fifty day simple moving average of $115.43 and a 200-day simple moving average of $106.53.

Novartis (NYSE:NVS) last released its quarterly earnings results on Thursday, July 18th. The company reported $1.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.10. The business had revenue of $12.87 billion during the quarter, compared to the consensus estimate of $12.24 billion. Novartis had a return on equity of 34.56% and a net margin of 33.76%. During the same quarter in the previous year, the company posted $1.83 EPS.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Private Ocean LLC acquired a new position in shares of Novartis during the 1st quarter valued at about $25,000. Richardson Financial Services Inc. purchased a new stake in shares of Novartis during the 4th quarter worth about $26,000. Clearstead Trust LLC grew its holdings in shares of Novartis by 73.5% during the 1st quarter. Clearstead Trust LLC now owns 269 shares of the company’s stock worth $26,000 after purchasing an additional 114 shares during the period. New Millennium Group LLC purchased a new stake in shares of Novartis during the 2nd quarter worth about $28,000. Finally, Lynx Investment Advisory purchased a new stake in shares of Novartis during the 2nd quarter worth about $29,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.